Jeffrey Hale, PhD is an Associate Vice President of Discovery Chemistry at Merck Research Laboratories. He is currently responsible for Merck's small molecule infectious diseases and neuroscience discovery efforts in West Point, Pennsylvania.
Jeff's thirty-three year tenure has seen him involved with, or leading, medicinal chemistry efforts targeting various metabolic disorder, immunoregulatory, and infectious disease targets. Jeff also has experience in process chemistry development and in research operations management.
Jeff received his B.S. in Chemistry in 1985 from Stevens Institute of Technology and his Ph.D. in 1992 from Rutgers University, where his research with Prof. Spencer Knapp involved novel protecting group chemistry and its application to alkaloid syntheses.
Jeff's research has been the subject of more than 50 publications and has led to 20 issued U.S. Patents. In 2005, he was awarded the Society of Chemical Industry (SCI) Gordon E. Moore medal for his pioneering work that led to the discovery and successful commercialization of the novel neurokinin-1 receptor antagonist, Emend®.
